Ciprofloxacin

Basic Information

CAS ID: 85721-33-1
Molecular Formula: C17H18FN3O3
Molecular Weight: 331.4 g/mol
Monoisotopic Mass: 331.1332 g/mol
Class: Small Molecule
Natural Product: No
Other Names: Velmonit | BAY O 9867 MONOHYDRATE | Ciloxan | CILOXAN | BAY-O-9867 | CIPRO | BAY Q 3939 | CETRAXAL | CIPROFLOXACIN | OTIPRIO | PROQUIN | PROQUIN XR | CIPROFLOXACIN HYDROCHLORIDE | Ciprofloxacin Lactate | Ciprobay
Analysis: Drug repositioning mechanism analysis

OH O N N NH F O

Compound Structure and Identifier

InChI: InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24) See All
InChI Key: MYSWGUAQZAJSOK-UHFFFAOYSA-N
Smiles: OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O See All
Molfile: Download

Related Target

Related Fibrosis Property

Reference Record 1

PubMed ID 11709326 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Reference Record 2

PubMed ID 11806288 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Reference Record 3

PubMed ID 11709326 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Trial Record 1

ClinicalTrial ID NCT01400750 Disease Cystic fibrosis
Phase Phase 4 Status Completed
First Received July 22, 2011 Last Verified August 4, 2011
Sponsor Universitaire Ziekenhuizen Leuven

Trial Record 2

ClinicalTrial ID NCT00645788 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received March 28, 2008 Last Verified June 9, 2014
Sponsor Bayer

Trial Record 3

ClinicalTrial ID NCT01090908 Disease Cystic fibrosis
Phase Status Withdrawn
First Received March 23, 2010 Last Verified August 29, 2012
Sponsor Aradigm Corporation

Trial Record 4

ClinicalTrial ID NCT00097773 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received December 1, 2004 Last Verified February 28, 2014
Sponsor Seattle Children's Hospital

Trial Record 5

ClinicalTrial ID NCT00153634 Disease Cystic fibrosis
Phase Not Applicable Status Completed
First Received September 12, 2005 Last Verified March 13, 2008
Sponsor Seattle Children's Hospital

Trial Record 6

ClinicalTrial ID NCT02015507 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received December 19, 2013 Last Verified March 26, 2014
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 7

ClinicalTrial ID NCT01768663 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received January 15, 2013 Last Verified November 15, 2013
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 8

ClinicalTrial ID NCT00910351 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received May 29, 2009 Last Verified November 21, 2013
Sponsor Bayer

Trial Record 9

ClinicalTrial ID NCT02555059 Disease Cystic fibrosis
Phase Status Completed
First Received September 21, 2015 Last Verified January 14, 2019
Sponsor Bayer

Trial Record 10

ClinicalTrial ID NCT01265173 Disease Liver fibrosis
Phase Phase 4 Status Completed
First Received December 23, 2010 Last Verified August 22, 2017
Sponsor Korea University

Trial Record 11

ClinicalTrial ID NCT00760032 Disease Liver fibrosis
Phase Phase 4 Status Withdrawn
First Received September 25, 2008 Last Verified December 5, 2012
Sponsor Florencia Vargas-Vorackova

Trial Record 12

ClinicalTrial ID NCT03027635 Disease Liver fibrosis
Phase Not Applicable Status Recruiting
First Received January 23, 2017 Last Verified May 28, 2018
Sponsor Nina Kimer

Trial Record 13

ClinicalTrial ID NCT02326103 Disease Liver fibrosis
Phase Early Phase 1 Status Completed
First Received December 25, 2014 Last Verified January 19, 2017
Sponsor Helsinki University

Related Link

PubChem: 4011971
ChEMBL: CHEMBL8